

Claims

1. A composition comprising
 - a. a human IL-12 protein comprising a first IL-12 subunit and a second IL-12 protein subunit;
 - b. a protein comprising an EDB binding domain; and
 - c. a linker between the IL-12 protein and the protein comprising the EDB binding domain;

wherein the composition comprises:

- a p40 domain linked to a p35 domain by a first linker;
- a first L19 VH domain linked to the p35 domain by a SAD linker;
- a first L19 VL domain linked to the first L19 VH domain by a third linker;
- a second L19 VH domain linked to the first L19 VL domain by a fourth linker;
- a second L19 VL domain linked to the second L19 VH domain by a fifth linker;

and wherein the composition has a full length sequence according to SEQ ID NO: 16.

2. Use of the composition according to claim 1 for the manufacture of a medicament for the treatment of a human or animal subject;

- being diagnosed with,
- suffering from, or
- being at risk of developing;

a neoplastic disease, or for the prevention of a neoplastic disease.

3. The use of claim 2, wherein the neoplastic disease is selected from the group consisting of malignant melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, urothelial carcinoma, head and neck squamous cell carcinoma (HNSCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer, hepatocellular

cancer, gastric cancer, squamous cell carcinoma of the skin, cervical cancer, and diffuse large B-cell lymphoma (DLBCL).

4. Use of the composition according to claim 1 in the manufacture of a medicament for the treatment of angiogenesis by tumor cells in cancer progression.

5. A pharmaceutical composition comprising the composition according to claim 1, and one or more pharmaceutically acceptable excipients.

6. A combination comprising (a) the composition according to claim 1 or the pharmaceutical composition according to claim 5 and (b) one or more therapeutically active compounds.

7. Use of the composition according to claim 1, the pharmaceutical composition according to claim 5, or the combination according to claim 6, in the manufacture of a medicament for the treatment of a disorder associated with overexpression of ED-B fibronectin.

8. A therapeutic kit of parts comprising:

- a) the composition according to claim 1, the pharmaceutical composition according to claim 5, or the combination according to claim 6
- b) an apparatus for administering the composition, pharmaceutical composition or combination, and
- c) instructions for use.